



Substitute Form PTO-1449 (MAY 2000)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. D3136CON1CIP RE	Application No. 10/820,563
Information Disclosure Statement by Applicant (Use several sheets if necessary)		Applicant Wong	
		Filing Date 04/08/2004	Group Art Unit 1616
(37 CFR §1.98(b))			

U.S. Patent Documents

Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
	AA	07/357,394					05/1989
	AB	07/386,835					07/1989
	AC	10/820,563					04/2004
	AD	60/587,092					07/2004
	AE	2004/0019098	01/2004	Andrews, et al.			
	AF	2004/0132824	07/2004	Gil, et al.			
	AG	2004/0137059	07/2004	Nivagioli, et al.			
	AH	2004/0151753	08/2004	Chen			
	AI	2004/0170665	09/2004	Donovan			
	AJ	2004/0266776	12/2004	Gil, et al.			
	AK	2005/0048099	03/2005	Shiah, et al.			
	AL	2005/0058696	03/2005	Donello, et al.			
	AM	2005/0059664	03/2005	Gil, et al.			
	AN	2005/0059744	03/2005	Donello, et al.			
	AO	2005/0101582	05/2005	Lyons, et al.			
	AP	2005/0181017	08/2005	Hughes, et al.			
	AQ	2005/0232966	10/2005	Hughes, et al.			
	AR	2005/0244464	11/2005	Hughes, et al.			
	AS	2005/0244469	11/2005	Whitcup, et al.			
	AT	2005/0244474	11/2005	Huang, et al.			
	AU	2006/0009498	01/2006	Whitcup			
	AV	2006/0233857	10/2006	Whitcup, et al.			
	AW	2006/0233859	10/2006	Whitcup, et al.			
	AX	2007/0224246	09/2007	Hughes, et al.			
	AY	2007/0298073	12/2007	Whitcup, et al.			
	AZ	3,416,530	12/1968	Ness			
	AAA	3,432,592	03/1969	Speiser			

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Disclosure Form (PTO-1449)



Substitute Form PTO-1449 (REMAINED)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. D3136CON1CIP RE	Application No. 10/820,563
Information Disclosure Statement by Applicant (Use several sheets if necessary)		Applicant Wong	
		Filing Date 04/08/2004	Group Art Unit 1616

(37 CFR §1.98(b))

U.S. Patent Documents

Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
	ABB	3,845,770	11/1974	Theeuwes, et al.			
	ACC	3,914,402	10/1975	Shell			
	ADD	3,916,899	11/1975	Theeuwes, et al.			
	AEF	3,921,632	11/1975	Bardani			
	AFF	3,961,628	06/1976	Arnold			
	AGG	3,986,510	10/1976	Higuchi, et al.			
	AHH	4,008,864	02/1977	Torphanmar, et al.			
	ALI	4,014,334	03/1977	Theeuwes, et al.			
	AJJ	4,063,064	12/1977	Saunders, et al.			
	AKK	4,088,864	05/1978	Theeuwes, et al.			
	ALL	4,144,317	03/1979	Higuchi, et al.			
	AMM	4,180,646	12/1979	Choi, et al.			
	ANN	4,186,184	01/1980	Zaffaroni			
	AOO	4,200,098	04/1980	Ayer, et al.			
	APP	4,201,210	05/1980	Hughes, et al.			
	AQQ	4,285,987	08/1981	Ayer, et al.			
	ARR	4,300,557	11/1981	Refojo, et al.			
	ASS	4,327,725	05/1982	Cortese, et al.			
	ATT	4,402,979	09/1983	Shen, et al.			
	AUU	4,451,254	05/1984	Dinius, et al.			
	AVV	4,474,451	10/1984	Mizokami			
	AWW	4,494,274	01/1985	Thurlow			
	AXX	4,521,210	06/1985	Wong			
	AYY	4,599,353	07/1986	Bito			
	AZZ	4,668,506	05/1987	Bawa			
	AAAA	4,756,911	07/1988	Drost, et al.			
	ABBB	4,801,460	01/1989	Goertz, et al.			

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Disclosure Form (PTO-1449)

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. D3136CON1CIP RE	Application No. 10/820,563
		Applicant Wong	
		Filing Date 04/08/2004	Group Art Unit 1616

**Information Disclosure Statement
by Applicant**

(Use several sheets if necessary)

(37 CFR §1.98(b))

U.S. Patent Documents

Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
	ACCC	4,806,337	02/1989	Snipes, et al.			
	ADDD	4,945,089	07/1990	Clark			
	AEEE	4,959,217	09/1990	Sanders, et al.			
	AFFF	4,966,849	10/1990	Vallee, et al.			
	AGGG	5,004,601	04/1991	Snipes			
	AHHH	5,004,614	04/1991	Staniforth			
	AIII	5,006,342	04/1991	Cleary, et al.			
	AJJJ	5,028,624	07/1991	Chan, et al.			
	AKKK	5,034,413	07/1991	Chan, et al.			
	ALLL	5,082,655	01/1992	Snipes, et al.			
	AMMM	5,314,419	03/1994	Pelling			
	ANNN	5,322,691	06/1994	Darougar, et al.			
	AOOO	5,330,992	07/1994	Eissenstat, et al.			
	APPP	5,384,333	01/1995	Davis, et al.			
	AQQQ	5,476,511	12/1995	Gwon, et al.			
	ARRR	5,601,844	02/1997	Kagayama, et al.			
	ASSS	5,660,847	08/1997	Magruder, et al.			
	ATTT	5,660,851	08/1997	Domb			
	AUUU	5,688,819	11/1997	Woodward, et al.			
	AVVV	5,693,335	12/1997	Xia, et al.			
	AWWW	5,755,785	05/1998	Rowsey, et al.			
	AXXX	5,773,019	06/1998	Ashton, et al.			
	AYYY	5,773,021	06/1998	Gurtler, et al.			
	AZZZ	5,824,074	10/1998	Koch			
	AAAAA	5,869,079	02/1999	Wong, et al.			
	ABBBB	5,882,682	03/1999	Rork, et al.			
	ACCCC	5,902,598	05/1999	Chen, et al.			

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Disclosure Form (PTO-1449)

Substitute Form PTO-1449 (Modified) Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))	U.S. Department of Commerce Patent and Trademark Office		Attorney's Docket No. D3136CON1CIP RE	Application No. 10/820,563
	Applicant Wong			
	Filing Date 04/08/2004		Group Art Unit 1616	

U.S. Patent Documents

Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
	ADDDD	5,941,250	08/1999	Aramant, et al.			
	AEEEE	5,962,027	10/1999	Hughes			
	AFFFF	5,972,369	10/1999	Roorda, et al.			
	AGGGG	6,045,791	04/2000	Liu			
	AHHHH	6,046,187	04/2000	Berde, et al.			
	AIIII	6,051,576	04/2000	Ashton, et al.			
	AJJJJ	6,063,116	05/2000	Kelleher			
	AKKKK	6,074,661	06/2000	Olejnuk, et al.			
	ALLLL	6,217,911	04/2001	Vaughn, et al.			
	AMMMM	6,309,669	10/2001	Setterstrom, et al.			
	ANNNN	6,329,369	12/2001	Chow, et al.			
	AOOOO	6,331,313	12/2001	Wong, et al.			
	APPPP	6,369,116	04/2002	Wong, et al.			
	AQQQQ	6,403,649	06/2002	Woodward, et al.			
	ARRRR	6,497,729	12/2002	Moussy, et al.			
	ASSSS	6,534,542	03/2003	Chow, et al.			
	ATTTT	6,537,568	03/2003	Olejnuk, et al.			
	AUUUU	6,545,182	04/2003	Chow, et al.			
	AVVVV	6,699,493	03/2004	Wong			
	AWWWW	6,713,081	03/2004	Robinson, et al.			
	AXXXX	6,726,918	04/2004	Wong, et al.			
	AYYYY	6,841,684	01/2005	Chow, et al.			
	AZZZZ	7,048,946	02/1999	Wong, et al.			
	AAAAAA	7,091,232	08/2006	Chow, et al.			
	ABBBBB	7,141,597	11/2006	Chow, et al.			
	ACCCCC	7,276,522	10/2007	Heidelbaugh, et al.			
	ADDDDD	7,335,803	02/2008	Chow, et al.			

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Disclosure Form (PTO-1449)

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. D3136CON1CIP RE	Application No. 10/820,563
		Applicant Wong	
		Filing Date 04/08/2004	Group Art Unit 1616

Information Disclosure Statement
by Applicant
(Use several sheets if necessary)

(37 CFR §1.98(b))

Foreign Patent Documents or Published Foreign Patent Applications								
Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
/J.H.A.A./	AEEEEEE	CA 2,336,703	01/2000	Canada				
/J.H.A.A./	AFFFFF	EP 0 052 916	07/1981	Europe				
/J.H.A.A./	AGGGGG	EP 0 197 718	03/1986	Europe			X	
/J.H.A.A./	AHHHHH	EP 0 322 319	06/1989	Europe				
/J.H.A.A./	AIIIII	EP 0 364 417	09/1989	Europe				
/J.H.A.A./	AJJJJJ	EP 0 430 539	06/1991	Europe				
/J.H.A.A./	AKKKKK	EP 0 488 401	06/1992	Europe				
/J.H.A.A./	ALLLLL	EP 0 654 256	05/1995	Europe				
/J.H.A.A./	AMMMMM	EP 0 992 244	04/2000	Europe				
/J.H.A.A./	ANNNNN	WO 1991/15495	10/1991	PCT				
/J.H.A.A./	AOOOOO	WO 1991/18940	12/1991	PCT			X	
/J.H.A.A./	APPPPP	WO 1992/21660	12/1992	PCT				
/J.H.A.A./	AQQQQQ	WO 1993/10141	05/1993	PCT			X	
/J.H.A.A./	ARRRRR	WO 1994/03427	02/1994	PCT				
/J.H.A.A./	ASSSSS	WO 1994/18956	09/1994	PCT				
/J.H.A.A./	ATTTTT	WO 1994/10202	05/1994	PCT				
/J.H.A.A./	AUUUUU	WO 1994/14808	07/1994	PCT				
/J.H.A.A./	AVVVVV	WO 1996/38174	12/1996	PCT			X	
/J.H.A.A./	AWWWWW	WO 1997/26869	07/1997	PCT			X	
/J.H.A.A./	AXXXXX	WO 1998/22130	05/1998	PCT				
/J.H.A.A./	AYYYYY	WO 1999/11244	03/1999	PCT				
/J.H.A.A./	AZZZZZ	WO 2000/02564	01/2000	PCT			X	
/J.H.A.A./	AAAAAAA	WO 2000/37056	06/2000	PCT				
/J.H.A.A./	ABBBBBB	WO 2000/62760	10/2000	PCT				
/J.H.A.A./	ACCCCCC	WO 2000/56340	09/2000	PCT			X	
/J.H.A.A./	ADDDDDD	WO 2001/30323	05/2001	PCT				
/J.H.A.A./	AEEEEEE	WO 2002/02076	01/2002	PCT				

Examiner Signature /James Alstrum Acevedo/	Date Considered 03/16/2009
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Disclosure Form (PTO-1449)

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /J.H.A.A./

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. D3136CON1CIP RE	Application No. 10/820,563
		Applicant Wong	
		Filing Date 04/08/2004	Group Art Unit 1616

Information Disclosure Statement
by Applicant
(Use several sheets if necessary)

(37 CFR §1.98(b))

Foreign Patent Documents or Published Foreign Patent Applications								
Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
/J.H.A.A./	AFFFFFF	WO 2002/43785	06/2002	PCT			X	
/J.H.A.A./	AGGGGGG	WO 2003/094888	05/2003	PCT			X	
/J.H.A.A./	AHHHHHH	WO 2004/026106	09/2003	PCT			X	
/J.H.A.A./	AIIIIII	WO 2004/062649	07/2004	PCT			X	
/J.H.A.A./	AJJJJJJ	WO 2005/110362	04/2005	PCT			X	
/J.H.A.A./	AKKKKKK	WO 2006/093758	09/2006	PCT			X	
/J.H.A.A./	ALLLLLL	WO 2007/130945	11/2007	PCT			X	

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
/J.H.A.A./	AMMMMMM	Aguilar, H.E., et al. "Vancomycin Levels After Intravitreal Injection," <i>Retina</i> , 1995; 15:428-432.
	ANNNNNN	Ahmad, M., et al. "Ortho Ester Hydrolysis: Direct Evidence for a Three-Stage Reaction Mechanism," <i>Journal of American Chemistry</i> , 1979; 101(10):2669-2677.
	AOOOOOO	Ahmed, I., et al. "Macular disorders: cystoid macular edema," <i>Ophthalmology</i> , Yanoff, M., Duker, J.S., eds. London: Mosby, 1999; 34.1-34.6.
	APPPPPP	Akduman, L., et al. "The early treatment diabetic retinopathy study," <i>Clinical trials in ophthalmology: a summary and practice guide</i> , Kertes, P.S., Conway, M.D., eds. Baltimore: Williams & Wilkins, 1998; 15-35.
	AQQQQQQ	Algvere, P.V., et al. "Transplantation of RPE in Age-Related Macular Degeneration: Observations in Disciform Lesions and Dry RPE Atrophy," <i>Graefe's Archives of Clinical Experimental Ophthalmology</i> , 1997; 235(3):149-158.
	ARRRRRR	Andreau, K., et al. "Induction of apoptosis by dexamethasone in the B cell lineage," <i>Immunopharmacology</i> , 1998 Jul; 40(1):67-76.
	ASSSSSS	Antcliff, R., et al. "The pathogenesis of edema in diabetic maculopathy," <i>Seminars in Ophthalmology</i> , 1999; 14:223-232.
	ATTTTTT	Apel, A., et al. "A Subconjunctival Degradable Implant for Cyclosporine Delivery in Corneal Transplant Therapy," <i>Current Eye Research</i> , 1995; 14(8):659-667.
	AUUUUUU	Araia, M., and Maurice, D.M. "The Loss of Fluorescein, Fluorescein Glucuronide and Fluorescein Isothiocyanate Dextran From the Vitreous by the anterior and Retinal Pathways," <i>Experimental Eye Research</i> , 1991; 52:27-39.
	AVVVVVV	Barnas, U., et al. "Parameters Associated with Chronic Renal Transplant Failure," <i>Nephrology Dialysis Transplantation</i> , 1997; 12(Suppl 2):82-85.
	WWWWWWW	Barza, M., et al. "Pharmacokinetics of Intravitreal Carbenicillin, Cefazolin, and Gentamicin in Rhesus Monkeys," <i>Investigative Ophthalmology & Visual Science</i> , 1983; 24:1602-1606.

Examiner Signature /James Alstrum Acevedo/	Date Considered 03/16/2009
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Disclosure Form (PTO-1449)

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. D3136CON1CIP RE	Application No. 10/820,563
		Applicant Wong	
		Filing Date 04/08/2004	Group Art Unit 1616

**Information Disclosure Statement
by Applicant**
(Use several sheets if necessary)

(37 CFR §1.98(b))

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
	AXXXXXX	Beck, R.W., et al. "The Effect of Corticosteroids for Acute Optic Neuritis on the Subsequent Development of Multiple Sclerosis," <i>New England Journal of Medicine</i> , 1993; 329(24):1764-1769.
	AYYYYYY	Beck, R.W., et al. "A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis," <i>New England Journal of Medicine</i> , 1992 Feb 27; 326(9):634-5.
	AZZZZZZ	Bennett, W.M. and Barry, J.M. "Failure of Dexamethasone to Provide Adequate Chronic Immunosuppression for Renal Transplantation," <i>Transplantation</i> , 1979; 27(3):218-219.
	AAAAAAA	Ben-Nun, J., et al. "Pharmacokinetics of Intravitreal Injection," <i>Investigative Ophthalmology & Visual Science</i> 1989; 30(6):1055-1061.
	ABBBBBB	Bigar, F. and C.P. Herbort. "Corneal Transplantation," <i>Current Opinion in Ophthalmology</i> , 1992; 3(4):473-481.
	ACCCCCC	Bingaman, D.P., et al. "Inhibition of preretinal neovascularization in pigs by intravitreal triamcinolone acetonide," <i>Investigative Ophthalmology and Visual Science</i> , 1995; 36(4):S401, abstract 1867.
	ADDDDDD	Bito, L.Z. "Prostaglandins and Related Compounds as Potential Ocular Therapeutic Agents," <i>Biological Protection with Prostaglandins</i> , Vol. 1, Cohen, M.M. ed., Boca Raton: CRC Press Inc., 1985; 31-252.
	AEEEEEE	Bito, L.Z. "Prostaglandins, Other Eicosanoids, and their Derivatives as Potential Antiglaucoma Agents," <i>Glaucoma: Applied Pharmacology in Medical Treatment</i> , Drance, S.M. and Neufeld, A.H. Eds., New York: Grune & Stratton, 1984; 477-505.
	AFFFFFF	Bito, L.Z. "Prostaglandins: Old Concepts and New Perspectives," <i>Archives of Ophthalmology</i> , 1987; 105:1036-1039.
	AGGGGGG	Bloch-Michel, E. "Opening Address: Intermediate Uveitis," <i>Developments in Ophthalmology: Intermediate Uveitis</i> , W.R.F. Böke, et al. eds. Basel: Karger, 1992; 23:1-2.
	AHHHHHH	Bodor, N., et al. "A Comparison of Intraocular Pressure Elevating Activity of Loteprednol Etabonate and Dexamethasone in Rabbits," <i>Current Eye Research</i> , 1992; 11(6):525-530.
	AIIIIII	Böke, W.R.F. "Clinical Picture of Intermediate Uveitis," <i>Developments in Ophthalmology: Intermediate Uveitis</i> , W.R.F. Böke, et al. eds. Basel: Karger 1992; (23):20-27.
	AJJJJJJ	Bolen, J.B. "Nonreceptor tyrosine protein kinases," <i>Oncogene</i> , 1993; 8(8):2025-2031.
/J.H.A.A./	AKKKKKK	Brubaker, R.F. "Mechanism of Action of Bimatoprost (Lumigan TM)," <i>Survey of Ophthalmology</i> , 2001; 45(Suppl 4):S347-S351.
	ALLLLLL	Budavari, S., et al. eds. <i>The Merck Index</i> , 12 th ed. Rahway, NJ: Merck and Co., 1996; Table of Contents only.
	MMMMMMM	Bundgaard, H. and Mess, J. "Prodrugs of Peptides IV: Bioreversible Derivatization of the Pyroglutamyl Group by N-Acylation and N-Aminomethylation to Effect Protection against Pyroglutamyl Aminopeptidase," <i>Journal of Pharmaceutical Sciences</i> , 1989; 78(2):122-126.
	ANNNNNN	Burdon, M.A. and P. McDonnell. "A Survey of Corneal Graft Practice in the United Kingdom," <i>Eye</i> , 1995; 9(Suppl):6-12.

Examiner Signature /James Alstrum Acevedo/	Date Considered 03/16/2009
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Disclosure Form (PTO-1449)

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. D3136CON1C1P RE	Application No. 10/820,563
		Applicant Wong	
		Filing Date 04/08/2004	Group Art Unit 1616

**Information Disclosure Statement
by Applicant**
(Use several sheets if necessary)

(37 CFR §1.98(b))

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
	A0000000	Chacko, D.M., et al. "Survival and Differentiation of Cultured Retinal Progenitors Transplanted in the Subretinal Space of the Rat," <i>Biochemical and Biophysical Research Communications</i> , 2000; 268(3):842-846.
	A9999999	Challa, J.K., et al. "Exudative Macular Degeneration and Intravitreal Triamcinolone: 18 month follow up," <i>Australian and New Zealand Journal of Ophthalmology</i> , 1998; 26:277-281.
	A9999999	Chang, David, et al. "Phase II results of an intraocular steroid delivery system for cataract surgery," <i>Ophthalmology</i> , 1996 June; 106(6):1172-1177.
	A9999999	Chen, J., et al. "Lumigan®: A Novel Drug for Glaucoma Therapy," <i>Optometry in Practice</i> , 2002; 3:95-102.
	A9999999	Clarkson, J.G. "Central retinal vein occlusion," <i>Retina</i> , 3 rd ed. Ryan, S., Schachar, A.P., eds. St. Louis, MO: CV Mosby; 2001; 1368-1375.
	A9999999	Coleman, A.L., et al. "A 3-Month Randomized Controlled Trial of Bimatoprost (LUMIGAN) Versus Combined Timolol and Dorzolamide (Cosopt) in Patients with Glaucoma or Ocular Hypertension," <i>Ophthalmology</i> , 2003; 110(12):2362-2368.
	A9999999	Cuff, G. and Raouf, F. "A Preliminary Evaluation of Injection Molding as a Technology to Produce Tablets," <i>Pharmaceutical Technology</i> , 1998; 96-106.
	A9999999	Davis, P.A., et al. "Intraocular Implant For Controlled 5-Fluorouracil Release," <i>Proceedings of the 19th International Symposium of Controlled Release Bioactive Materials</i> , 1992; 19:339-340.
	A9999999	De Jong, S.J., et al. "New insights into the hydrolytic degradation of poly(lactic acid): participation of the alcohol terminus," <i>Polymer</i> , 2001; 42:2795-2802.
	A9999999	Dick, J., et al. "Macular edema," <i>Retina</i> , 3 rd ed. Ryan, S., Schachar, A.P., eds. St. Louis, MO: CV Mosby; 2001; 967-979.
	A9999999	Dinning, W.J. "Intermediate Uveitis: history, terminology definition pars planitis: systemic disease associations," <i>Developments in Ophthalmology: Intermediate Uveitis</i> , W.R.F. Böke, et al. eds. Basel: Karger, 1992; 3-8.
	A9999999	Dohlman, C., et al. "Treatment of corneal edema with a buried implant," <i>Transactions: American Academy of Ophthalmology and Otolaryngology</i> , 1966 Mar-Apr; 267-280.
	A9999999	Druilhe, A., et al. "Glucocorticoid-induced apoptosis in human eosinophils: mechanisms of action," <i>Apoptosis</i> , 2003 Oct; 8(5):481-95.
	A9999999	Encyclopedia of Polymer Science and Technology, vol. 3. New York: Interscience Publishers, Inc., 2003; Table of Contents only, v.
	A9999999	Enzmann, V., et al. "Immunological Problems of Transplantation into the Subretinal Space," <i>Acta Anatomica</i> , 1998; 162(2-3):178-183.
	A9999999	Fatt, I. "Flow and Diffusion in the Vitreous Body of The Eye," <i>Bulletin of Mathematical Biology</i> , 1975; 37:85-90.
	A9999999	Fekrat, S. and Finkelstein, D. "The Central Vein Occlusion Study," <i>Clinical trials in ophthalmology: a summary and practice guide</i> , Kertes, P.S., Conway, M.D., eds. Baltimore, MD: Williams & Wilkins, 1998; 129-143.
	A9999999	Frank, R.N. "Etiologic mechanisms in diabetic retinopathy," <i>Retina</i> , 3 rd ed. Ryan, S., Schachar, A.P., eds. St. Louis, MO: CV Mosby; 2001; 1259-1294.

Examiner Signature James Alstrum Acevedo/	Date Considered 03/16/2009
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Disclosure Form (PTO-1449)

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /J.H.A./

Substitute Form PTO-1449 (Modified) Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. D3136CON1CIP RE	Application No. 10/820,563
		Applicant Wong	
		Filing Date 04/08/2004	Group Art Unit 1616

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
	GGGGGGGG	Friedrich, S., et al. "Finite Element Modeling of Drug Distribution in the Vitreous Humor of the Rabbit Eye," <i>Annals of Biomedical Engineering</i> , 1997; 25:303-314.
	HHHHHHHH	Gennaro, A.R. ed. <i>Remington: The Science and Practice of Pharmacy</i> , 19 th Ed. Easton, PA: Mack Publishing Company, 1995; Table of Contents only, xv-xvi.
	IIIIIIII	Gillies, M.C., et al. "Safety of an intravitreal injection of triamcinolone," <i>Archives of Ophthalmology</i> , 2004 Mar; 122:336-340.
	JJJJJJJJ	Gilman, A.G., et al. eds. <i>Goodman and Gilman's: The Pharmacological Basis of Therapeutics</i> , 8 th Ed. New York: Pergamon Press, 1990; Table of Contents only, xi-xvi.
	KKKKKKKK	Goldberg, Ivan, "Drugs for glaucoma," <i>Australian Prescriber</i> , 2002; 25(6):142-146.
	LLLLLLLL	Goodman, L.S. and A. Gilman eds. <i>The Pharmacological Basis of Therapeutics</i> , 9 th Ed. New York: McGraw-Hill, 1996; Table of Contents only, v-xii.
	MMMMMMMM	Gould, L., et al. "Fifty-fifty Poly (DL Glycolic Acid-Lactic Acid) Copolymer as a Drug Delivery System for 5-Fluorouracil: A Histopathological Evaluation," <i>Canadian Journal of Ophthalmology</i> , 1994; 29(4):168-171.
	NNNNNNNN	Greenfield, R.S., et al. "Evaluation <i>in Vitro</i> of Adriamycin Immunoconjugates Synthesized Using an Acid-sensitive Hydrazone Linker," <i>Cancer Research</i> , 1990; 50:6600-6607.
	OOOOOOOO	Guan, D., et al. "The Therapeutic Window of Cyclosporine in Chinese Recipients of Renal Transplantation," <i>Transplantation Proceedings</i> , 1995; 27(1):850-851.
	PPPPPPPP	Hari, P. and Srivastava, R.N. "Pulse Corticosteroid Therapy with Methylprednisolone or Dexamethasone," <i>Indian Journal of Pediatrics</i> , 1998; 65(3):557-560.
	QQQQQQQQ	Haynes, Robert C. Jr. "Adrenocorticotrophic Hormone; Adrenocortical Steroids and their Synthetic Analogs; Inhibitors of the Synthesis and Actions of Adrenocortical Hormones," <i>Goodman and Gilman's: The pharmacological Basis of Therapeutics</i> , 8th Ed. New York: Pergamon Press, 1990; 1431-1462.
	RRRRRRRR	Hayreh, S.S. "Posterior Drainage of the Intraocular Fluid From the Vitreous," <i>Experimental Eye Research</i> , 1996; 5:123-144.
	SSSSSSSS	Heller, J. "Poly (Ortho Esters)," <i>Biopolymers I</i> , Peppas, N.A. and R.S. Langer eds. New York: Springer-Verlag, 1993; 41-92.
	TTTTTTTT	Heller, J., et al. "Poly(ortho ester) Biodegradable Polymer Systems," <i>Methods in Enzymology</i> , Widdler, K.J. and R. Green eds. Orlando: Academic Press, Inc., 1985; 422-436.
	UUUUUUUU	Hirano, T. "Clinical Significance of Glucocorticoid Pharmacodynamics Assessed by Antilymphocyte Action in Kidney Transplantation," <i>Transplantation</i> , 1994; 57(9):1341-1348.
	VVVVVVVV	Inoue, M., et al. "Vitreous Concentrations of Triamcinolone Acetonide in Human Eyes After Intravitreal or Subtenon Injection," <i>American Journal of Ophthalmology</i> , 2004; 138(6):1046-8.
	WWWWWWW	Jaffe, G.J., et al. "Safety and Pharmacokinetics of an Intraocular Fluocinolone Acetonide Sustained Delivery Device," <i>Investigative Ophthalmology & Visual Science</i> , 2000; 41(11):3569-3575.

Examiner Signature /James Alstrum Acevedo/	Date Considered 03/16/2009
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Disclosure Form (PTO-1449)

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. D3136CON1CIP RE	Application No. 10/820,563
		Applicant Wong	
		Filing Date 04/08/2004	Group Art Unit 1616

**Information Disclosure Statement
by Applicant**

(Use several sheets if necessary)

(37 CFR §1.98(b))

Other Documents (include Author, Title, Date, and Place of Publication)

Examiner Initial	Desig. ID	Document
	XXXXXXXX	Jaffe, G.J., et al. "Safety, Efficacy, and Pharmacokinetics of an Intravitreal Fluocinolone Sustained Drug Delivered System," <i>Investigative Ophthalmology & Visual Science</i> , 1999; 40(4):S988, abstract 5195.
	YYYYYYYY	Jay, W.M., et al. "Intravitreal Cefazidime in a Rabbit Model: Dose- and Time-Dependent Toxicity and Pharmacokinetic Analysis," <i>Journal of Ocular Pharmacology</i> , 1987; 3(3):257-262.
	AZZZZZZZ	Jellinek, D., et al. "Inhibition of Receptor binding by High-affinity RNA Ligands to Vascular Endothelial Growth Factor," <i>Biochemistry</i> , 1994; 33:10450-56.
	AAAAAAAA	Jennings, T., et al. "Posterior sub-Tenon's injections of corticosteroids in uveitis patients with cystoid macular edema," <i>Japanese Journal of Ophthalmology</i> , 1988; 32(4):385-391.
	BBBBBBBB	Jeong, J.H., et al. "Novel Intracellular Delivery System of Antisense Oligonucleotide by Self-Assembled Hybrid Micelles Composed of DNA/PEG Conjugate and Cationic Fusogenic Peptide," <i>Bioconjugate Chemistry</i> , 2003; 14:473-479.
	CCCCCCCC	Johnson, F. and Maurice, D. "A Simple Method of Measuring Aqueous Humor Flow With Intravitreal Fluoresceinated Dextran," <i>Experimental Eye Research</i> , 1984; 39:791-805.
	DDDDDDDD	Jonas, J.B., et al. "Intraocular pressure after intravitreal injection of triamcinolone acetonide," <i>British Journal of Ophthalmology</i> , 2003; 87:24-27.
	EEEEEEEE	Kane, A., et al. "Intravitreal Injection of Gentamicin in Rabbits," <i>Investigative Ophthalmology & Visual Science</i> , 1981; 20(5):593-597.
	FFFFFFFF	Kang, S.W., et al. "Macular grid photocoagulation after intravitreal triamcinolone acetonide for diffuse diabetic macular edema," <i>Archives of Ophthalmology</i> , 2006 May; 124(5):653-8.
	GGGGGGGG	Kendall, R.L. and K.A. Thomas. "Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor," <i>Proceedings of the National Academy of Science USA</i> , 1994; 90:10705-09.
	HHHHHHHH	Kher, V., et al. "Low-Dose Dexamethasone- An Alternative Therapy for Acute Renal Allograft Rejection," <i>Transplantation Proceedings</i> , 1992; 24(5):1725.
	IIIIIIII	Kim, K.J., et al. "Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth <i>in vivo</i> ," <i>Nature</i> , 1993; 362(6423):841-844.
	JJJJJJJJ	Kimura, H. and Ogura, Y. "Biodegradable Polymers for Ocular Drug Delivery," <i>Ophthalmologica</i> , 2001; 215:143-155.
	KKKKKKKK	Kinsella, J.L., et al. "Protein Kinase C Regulates Endothelial Cell Tube Formation on Basement Membrane Matrix, Matrigel," <i>Experimental Cell Research</i> , 1992; 199:56-62.
	LLLLLLLL	Kochinke, F. and Wong, V.G. "Biodegradable Drug Delivery System for Uveitis Treatment, Oculex Pharmaceuticals, Inc.," Slide Presentation, 1996; total pages 20.
	MMMMMM	Kralinger, M.T., et al. "Slow Release of Acetylsalicylic Acid by Intravitreal Silicone Oil," <i>Retina: The Journal of Retinal and Vitreous Diseases</i> , 2001; 21(5):513-520.
	NNNNNNNN	Kunou, Noriyuki, et al. "Biodegradable scleral implant for controlled intraocular delivery of betamethasone phosphate," <i>Journal of Biomedical Materials Research</i> , 2000; 51(4):635-641.
	OOOOOOOO	Kwak, H.W. and D'Amico, D.J. "Evaluation of the Retinal Toxicity and Pharmacokinetics of Dexamethasone After Intravitreal Injection," <i>Archives of Ophthalmology</i> , 1992; 110:259-266.

Examiner Signature /James Alstrum Acevedo/	Date Considered 03/16/2009
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Disclosure Form (PTO-1449)

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /J.H.A.A./

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. D3136CON1CIP RE	Application No. 10/820,563
		Applicant Wong	
		Filing Date 04/08/2004	Group Art Unit 1616

Information Disclosure Statement
by Applicant
(Use several sheets if necessary)

(37 CFR §1.98(b))

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
/J.H.A.A./	APPPPPPPPP	Laurent, U.B.G. and Fraser, J.R.E. "Turnover of Hyaluronate in the Aqueous Humor And Vitreous Body of the Rabbit," <i>Experimental Eye Research</i> , 1983; 36:493-504.
/J.H.A.A./	QQQQQQQQQ	Lec, K.Y. and Wong, V.G. "Dexamethasone Posterior Segment Drug Delivery System for Treatment of Severe Uveitis," <i>American Uveitis Society</i> , 1999; Abstract.
/J.H.A.A./	RRRRRRRRR	Lee, V.H.L., et al. "Drug Delivery to the Posterior Segment" <i>Retina</i> , 3 rd ed. T.E. Ogden and A.P. Schachar eds. St. Louis: CV Mosby, 1989; 483-498.
/J.H.A.A./	ASSSSSSSS	Leopold, I.H. "Nonsteroidal and steroidal anti-inflammatory agents," <i>Surgical pharmacology of the Eye</i> , Sears, M., Tarkkanen, A., eds. New York: Raven Press, 1985; 83-133.
/J.H.A.A./	ATTTTTTTTT	Marcon, I. "A double-masked comparison of betaxolol and levobunolol for the treatment of primary open-angle glaucoma," <i>Arquivos Brasileiros de Oftalmologia</i> , 1990; 53(1):27-32.
/J.H.A.A./	AUUUUUUUU	Mariani, M., et al. "Inhibition of angiogenesis by FCE 26806, a potent tyrosine kinase inhibitor," <i>Proceedings of the American Association for Cancer Research</i> , 1994; 35:381, abstract 2268.
/J.H.A.A./	VVVVVVVVV	Mathebulu, S.D. "A Review of Pharmacological Therapy for Glaucoma," <i>The South African Optometrist</i> , 2005 Sept; 64(3):89-96.
/J.H.A.A./	VWWWWWW	Maurice, D.M. "The Exchange of Sodium Between The Vitreous Body and The Blood And Aqueous Humour," <i>Journal of Physiology</i> , 1957; 137:110-125.
/J.H.A.A./	AXXXXXXXXX	Maurice, D.M. "Flow of Water Between Aqueous and Vitreous Compartments in the Rabbit Eye," <i>American Journal of Physiology</i> , 1987; 252 (1):F104-F108.
/J.H.A.A./	AYYYYYYYYY	Maurice, D.M. "Micropharmaceutics of the Eye," <i>Ocular Inflammation and Therapeutics</i> , 1983; 1:97-102.
J.H.A.A./	AZZZZZZZZ	Maurice, D.M. and Mishima, S. "Ocular Pharmacokinetics," <i>Pharmacology of the Eye</i> , M.L. Sears ed. New York: Springer-Verlag, 1984; 19-116.
/J.H.A.A./	AAAAAAAAA	Meadows, D.L., et al. "Ocular Drug Delivery with Subconjunctival Implants," <i>Proceedings of the International Symposium on Controlled Release of Bioactive Materials</i> , Controlled Release Society, Inc., 1994; 21:593-594.
/J.H.A.A./	ABBBBBBBBB	Migita, K., et al. "Apoptosis Induction in Human Peripheral Blood T Lymphocytes by High-Dose Steroid Therapy", <i>Transplantation</i> , 1997; 63(4):583-587.
/J.H.A.A./	ACCCCCCCCC	Mittal, R., et al. "Treatment of Acute Rejection in Live Related Renal Allograft Recipients: A Comparison of Three Different Protocols," <i>Nephron</i> , 1977; 77(2):186-189.
/J.H.A.A./	ADDDDDDDDD	Molfino, F., et al. "IOP-lowering effect of dorzolamide 2% versus brimonidine tartrate 0.2%. A prospective randomized cross over study," <i>Investigative Ophthalmology & Visual Science</i> , 1998 Mar; 39(4):S481.
/J.H.A.A./	EEEEEEEEEE	Morita Y., et al. "Intravitreal delivery of dexamethasone sodium <i>m</i> -sulfolbenzoate from poly (DL-lactic acid) implants," <i>Biological & Pharmaceutical Bulletin</i> , 1998 Feb; 21(2):188-90.
/J.H.A.A./	FFFFFFTTTT	Morita, Y., et al. "Polymer Blend Implant for Ocular Delivery of Fluorometholone," <i>Biological & Pharmaceutical Bulletin</i> , 1998; 21(1):72-75.
/J.H.A.A./	GGGGGGGGG	Moseley, H., et al. "Routes of Clearance of Radioactive Water From The Rabbit Vitreous," <i>British Journal of Ophthalmology</i> , 1984; 68:145-151.

Examiner Signature /James Alstrum Acevedo/	Date Considered 03/16/2009
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Disclosure Form (PTO-1449)

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /J.H.A.A./

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. D3136CON1CIP RE	Application No. 10/820,563
Information Disclosure Statement by Applicant (Use several sheets if necessary)		Applicant Wong	
		Filing Date 04/08/2004	Group Art Unit 1616
(37 CFR §1.98(b))			

Other Documents (Include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
Eng. Abs. Only	HHHHHHHHH	Nakamura, O., et al. "Inhibition of neovascularization and tumor growth by dexamethasone," <i>No To Shinkei (Brain and Nerve)</i> , 1992 Jan; 44(1):37-41.
/J.H.A.A./	AAAAAAAA	Nauck, M., et al. "Corticosteroids inhibit the expression of the vascular endothelial growth factor gene in human vascular smooth muscle cells," <i>European Journal of Pharmacology</i> , 1998; 341:309-315.
/J.H.A.A./	AJJJJJJJJ	Nauck, M., et al. "Induction of vascular endothelial growth factor by platelet-activating factor and platelet-derived growth factor is downregulated by corticosteroids," <i>American Journal of Respiratory Cell and Molecular Biology</i> , 1997; 16:398-406.
/J.H.A.A./	KKKKKKKKK	Nilsson, S.F.E., et al. "PGF2 Increases Uveoscleral Outflow," <i>Investigative Ophthalmology & Visual Science</i> , 1987; 28(3):284, abstract 9.
/J.H.A.A./	LLLLLLLLL	Ogden, T.E., et al. eds. <i>Retina - Basic Science and Inherited Retinal Disease Vol. I</i> , St. Louis: CV Mosby, 1994; Table of Contents, xxiii-xxix.
/J.H.A.A./	MMMMMM	Ohtori, A. and Tojo, K. "In vivo/in Vitro Correlation of Intravitreal Delivery of Drugs With the Help of Computer Simulation," <i>Biological & Pharmaceutical Bulletin</i> , 1994; 17(2):283-290.
/J.H.A.A./	NNNNNNNNN	Olsen, T.W., et al. "Human Scleral Permeability: Effects of Age, Cryotherapy, Transscleral Diode Laser, and Surgical Thinning," <i>Investigative Ophthalmology & Visual Science</i> , 1995; 36(9):1893-1903.
/J.H.A.A./	OOOOOOOOO	Oplinger, N.L., et al. "A Comparison of Corneal Autografts With Homografts," <i>Ophthalmic Surgery and Lasers</i> , 1998; 29(4):305-308.
/J.H.A.A./	PPPPPPPPP	Orth, D. "The branch vein occlusion study," <i>Clinical trials in ophthalmology: A summary and practice guide</i> , Kertes, P, and Conway, M, eds., Baltimore, MD: Williams & Wilkins, 1998: 113-127.
/J.H.A.A./	QQQQQQQQQ	Park, T.G., et al. "A new preparation method for protein loaded poly (D,L-lactic-co-glycolic acid) microspheres and protein release mechanism study," <i>Journal of Controlled Release</i> , 1998; 55: 181-191.
/J.H.A.A./	RRRRRRRRR	Patel, N.P., et al. "Indications for and Outcomes of Repeat Penetrating Keratoplasty, 1989-1995," <i>Ophthalmology</i> , 2000; 107(4):719-724.
/J.H.A.A./	SSSSSSSSS	Pearson, P.A., et al. "Clearance and Distribution of Ciprofloxacin After Intravitreal Injection," <i>Retina</i> , 1993; 13:326-330.
/J.H.A.A./	TTTTTTTTT	Pe'er, J., et al. "Vascular endothelial growth factor by platelet-activating factor upregulation in human central retinal vein occlusion," <i>Ophthalmology</i> , 1998; 105:412-416.
/J.H.A.A./	UUUUUUUUU	Peyman, G.A. and Herbst, R. "Bacterial endophthalmitis," <i>Archives of Ophthalmology</i> , 1974; 91(5):416-418.
/J.H.A.A./	VVVVVVVVV	Peyman, G.A., et al. "A Technique for Retinal Pigment Epithelium Transplantation for Age-Related Macular Degeneration Secondary to Extensive Subfoveal Scarring," <i>Ophthalmic Surgery</i> , 1991; 22(2):102-108.
/J.H.A.A./	WWWWWWW	Pinar, V. "Intermediate Uveitis," <i>Massachusetts Eye & Ear Infirmary Immunology Service</i> , Boston.
/J.H.A.A./	XXXXXXXXX	Plowman, G.D., et al. "Receptor Tyrosine Kinases as Targets for Drug Intervention," <i>Drug News & Perspectives</i> , 1994; 7(6): 334-339.

Examiner Signature /James Alstrum Acevedo/	Date Considered 03/16/2009
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Disclosure Form (PTO-1449)

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /J.H.A.A./

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. D3136CON1CIP RE	Application No. 10/820,563
		Applicant Wong	
		Filing Date 04/08/2004	Group Art Unit 1616

**Information Disclosure Statement
by Applicant**
(Use several sheets if necessary)

(37 CFR §1.98(b))

Other Documents (include Author, Title, Date, and Place of Publication)			
Examiner Initial	Desig. ID	Document	
/J.H.A.A./	YYYYYYYY	Rahil, J., et al. "Reactivity and Mechanism of Hydrolysis of Phosphonamides," <i>Journal of the American Chemical Society</i> , 1981; 103:1723-1734.	
/J.H.A.A./	ZZZZZZZZ	Rao, K.V., et al. "Successful Renal Transplantation in a Patient With Anaphylactic Reaction to Solu-Medrol (Methylprednisolone Sodium Succinate)," <i>American Journal of Medicine</i> , 1982; 72(1):161-163.	
/J.H.A.A./	AAAAAAAAAA	Rao, N.A., et al. "Intraocular Inflammation and Uveitis," <i>Basic and Clinical Science Course</i> , Section 9, San Francisco: American Academy of Ophthalmology, 1998-1999; 57-80, 102-103, 152-156.	
/J.H.A.A./	BBBBBBBBBB	Renfro, L. and Snow, J.S. "Ocular Effects of Topical and Systemic Steroids," <i>Dermatologic Clinics</i> , 1992; 10:505-512.	
/J.H.A.A./	CCCCCCCCC	Riordan-Eva, P., et al. "Orbital floor steroid injections in the treatment of uveitis," <i>Eye</i> , 1994; 8(1):66-69.	
/J.H.A.A./	DDDDDDDDDD	Robin, Jeffrey B., et al. "The Histopathology of Corneal Neovascularization," <i>Archives of Ophthalmology</i> , 1985; 103(2):284-287.	
/J.H.A.A./	EEEEEEEEEE	Roff, W.J. and Scott, J.R. eds. <u>Handbook of Common Polymers</u> , Cleveland: CRC Press, 1971; Table of Contents.	
/J.H.A.A./	FFFFFFFFFFFF	Rootman, D.S., et al. "Toxicity and Pharmacokinetics of Intravitreally Injection Ciprofloxacin in Rabbit Eyes," <i>Canadian Journal of Ophthalmology</i> , 1992; 27(6):277-282.	
/J.H.A.A./	GGGGGGGGGG	Sasaki, H., et al. "Drug Absorption Behavior After Periocular Injections," <i>Biological & Pharmaceutical Bulletin</i> , 1999; 22(9):956-960.	
/J.H.A.A./	HHHHHHHHHH	Schimmer B.P. and Parker K.L. "Adrenocorticotrophic hormone; Adrenocortical Steroids and their Synthetic Analogs; Inhibitors of the Synthesis and Actions of Adrenocortical Hormones," <i>The Pharmacological Basis of Therapeutics</i> 10 th ed., Hardman, J.G. and Limbard, L.L. eds, New York: McGraw-Hill, 2001; 1649-1677.	
/J.H.A.A./	IIIIIIIIII	Schindler, R.H., et al. "The Clearance of Intravitreal Triamcinolone Acetonide," <i>American Journal of Ophthalmology</i> , 1982; 93(4):415-417.	
/J.H.A.A./	JJJJJJJJJJ	Scholes, G.N., et al. "Clearance of Triamcinolone From Vitreous," <i>Archives of Ophthalmology</i> , 1985; 103(10):1567-1569.	
/J.H.A.A./	KKKKKKKKKK	Schwartz, B. "The Response of Ocular Pressure to Corticosteroids," <i>International Ophthalmology Clinics</i> , 1966; 6:929-989.	
/J.H.A.A./	LLLLLLLLLL	Scott, J.R. and W.J. Roff eds. "Permeability," <u>Handbook of Common Polymers</u> , Cleveland: CRC Press, 1971; 554-558.	
/J.H.A.A./	MMMMMMMM	Siebold, et al. <i>Prodrug</i> , 1989; 5:3.	
/J.H.A.A./	NNNNNNNNNN	Skalka, H.W. and Prchal, J.T. "Effect of Corticosteroids on Cataract Formation," <i>Archives of Ophthalmology</i> , 1980; 98(10):1773-1777.	
/J.H.A.A./	OOOOOOOOOO	Starr, M.S. "Further Studies on the Effect of Prostaglandin on Intraocular Pressure in the Rabbit," <i>Experimental Eye Research</i> , 1971; 11(2):170-177.	
/J.H.A.A./	PPPPPPPPPP	Stewart, W., et al. "Washout periods for brimonidine 0.2% and latanoprost 0.005%," <i>American Journal of Ophthalmology</i> , 2001 June; 131(6):798-799.	
/J.H.A.A./	QQQQQQQQQQ	Taba, K.E., et al. "Intravitreal sustained release fluocinolone implant inhibits experimental choroidal neovascularization," <i>Investigative Ophthalmology & Visual Science</i> , 1999 Mar; 40(4):S172, abstract 920.	
Examiner Signature		Date Considered	
/James Alstrum Acevedo/		03/16/2009	
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			

Substitute Disclosure Form (PTO-1449)

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /J.H.A.A./

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. D3136CON1CIP RE	Application No. 10/820,563
		Applicant Wong	
		Filing Date 04/08/2004	Group Art Unit 1616

**Information Disclosure Statement
by Applicant**
(Use several sheets if necessary)

(37 CFR §1.98(b))

Other Documents (include Author, Title, Date, and Place of Publication)

Examiner Initial	Desig. ID	Document
/J.H.A.A./	RRRRRRRRRR	Takano, S., et al. "Inhibition of Angiogenesis by a Novel Diaminoanthraquinone that Inhibits Protein Kinase C," <i>Molecular Biology of the Cell</i> , 1993; 4:358A, abstract 2076.
/J.H.A.A./	SSSSSSSSSS	Tan, D.T.H., et al. "Randomized Clinical Trial of a New Dexamethasone Delivery System (Surodex) for Treating of Post-Cataract Surgery Inflammation," <i>Ophthalmology</i> , 1999; 106(2):223-231.
/J.H.A.A./	TTTTTTTTTT	Tennant, J.L. "Cystoid maculopathy," <i>Current concepts in cataract surgery: selected proceedings of the fifth biennial cataract surgical congress</i> , Emery, J.M. ed. St. Louis: CV Mosby, 1978; 360-362.
/J.H.A.A./	UUUUUUUUUU	Theng, J.T.S., et al. "Pharmacokinetic and Toxicity Study of an Intraocular Cyclosporine DDS in the Anterior Segment of Rabbit Eyes," <i>Investigative Ophthalmology & Visual Science</i> , 2003 Nov; 44(11):4895-4899.
/J.H.A.A./	VVVVVVVVVV	Tracy, M.A., et al. "Factors affecting the degradation rate of poly(lactide-co-glycolide) microspheres in vivo and in vitro," <i>Biomaterials</i> , 1999; 20:1057-1062
/J.H.A.A./	VVVVVVVVVV	Tsubota, K. "Ocular Surface Management in Corneal Transplantation, A Review," <i>Japanese Journal of Ophthalmology</i> , 1999; 43(6):502-508.
/J.H.A.A./	XXXXXXXXXX	Turcotte, J.G., et al. "Rejection Crises in Human Renal Transplant Recipients: Control with High Dose Methylprednisolone Therapy," <i>Archives of Surg</i> , 1972; 105(1):230-236.
/J.H.A.A./	YYYYYYYYYY	<u>The United States Pharmacopeia, The National Formulary, "USP 24/NF 19," 2000; 1941-1951.</u>
/J.H.A.A./	ZZZZZZZZZZ	Watson, P., et al. "A Six-month, Randomized, Double-masked Study Comparing Latanoprost with Timolol in Open-angle Glaucoma and Ocular Hypertension," <i>Ophthalmology</i> , 1996; 103(1):126-137.
/J.H.A.A./	AAAAAAAAAA	Weisbecker, C.A., et al., eds. <i>Physicians' Desk Reference for Ophthalmology 27th ed.</i> , Montvale, NJ: Medical Economics Company, 1998; 7-8, 278-279.
/J.H.A.A./	BBBBBBBBBB	Wingate, R.J., et al. "Intravitreal Triamcinolone and Elevated Intraocular Pressure," <i>Australian and New Zealand Journal of Ophthalmology</i> , 1999 Dec; 27(6):431-2.
/J.H.A.A./	CCCCCCCC	Woodward, D.F., et al. "AGN 192024 (Lumigan®): A Synthetic Prostanoid Analog that Lowers Primate Intraocular Pressure by Virtue of Its Inherent Pharmacological Activity," <i>Investigative Ophthalmology & Visual Science</i> , 2002; 43, abstract 4110.
/J.H.A.A./	DDDDDDDDDD	Woodward, D.F., et al. "The Pharmacology of Bimatoprost (Lumigan TM)," <i>Survey of Ophthalmology</i> , 2001; 45(Suppl 4):S337-S345.
/J.H.A.A./	EEEEEEEEEE	Wright, P.S., et al. "Inhibition of Angiogenesis In Vitro and In Ovo with an Inhibitor of Cellular Protein Kinases, MDL 27032," <i>Journal of Cellular Physiology</i> , 1992; 152(3):448-457.
/J.H.A.A./	FFFFFFFFFFFF	Xu, J., et al. "Permeability and Diffusion in Vitreous Humor: Implications for Drug Delivery," <i>Pharmaceutical Research</i> , 2000; 17(6):664-669.
/J.H.A.A./	GGGGGGGG	Zhou, T., et al. "Development of a Multiple-Drug Delivery Implant for Introcular Management of Proliferative Vitreoretinopathy," <i>Journal of Controlled Release</i> , 1998; 55:281-295.

Examiner Signature /James Alstrum Acevedo/	Date Considered 03/16/2009
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Disclosure Form (PTO-1449)